Brendan has worked in the rapid diagnostics field for over 20 years in various R&D, Manufacturing and Management capacities. Having gained a Ph.D. in Medical Microbiology from University College Dublin, he began his commercial career in the rapid diagnostics business at Trinity Biotech in Dublin as a development team leader. After immigrating to the US, he became Director of R&D, and later, the Director of Manufacturing at Saliva Diagnostic Systems in Vancouver, WA. Here, he was responsible for the development and manufacturing of a wide range of FDA-regulated medical diagnostic products. Upon moving to California, Brendan became Vice President of Technology Development at BioDot Inc. At BioDot, he was responsible for the engineering and process development groups. He also established The One Step…One Solution (OSOS) Program, which was a successful assay development and consulting division of BioDot’s business. In 2005, Brendan and DCN co-founder, Michael Surmanian, effected a management buyout of the OSOS business and transitioned it into DCN.
High Performance Field-based Immunosensor Platforms Based on Next-Generation Lateral Flow Technology
Tuesday, 27 September 2016 at 13:30
Add to Calendar ▼2016-09-27 13:30:002016-09-27 14:30:00Europe/LondonHigh Performance Field-based Immunosensor Platforms Based on Next-Generation Lateral Flow TechnologyPoint-of-Care Diagnostics and Global Health World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
A traditional continuum exists in diagnostic platform performance that ranges from highly accurate methods that require infrastructure and a centralized approach to testing to less accurate technologies that can be used in a decentralized or point of care testing strategy and that require little to no supporting infrastructure. Lab-based molecular diagnostic technologies have traditionally occupied one end of that scale, while lateral flow has dominated the other end. Other testing methodologies such as ELISA, Western Blot and even more novel “point of care” molecular platform technologies tend to fall between these two extremes. However, few immuno-sensor or point of care molecular chips or sensors match the combination of utility, performance, manufacturability, availability, supplier ecosystem and regulatory and market acceptance that lateral flow assays demonstrate. Over the last decade, advances in technology, manufacturing processes and device design have allowed for significant evolution in the lateral flow platform and adoption in applications that would not previously have been considered for this sensor type. In this presentation, the drivers of improved performance in next generation lateral flow based sensor platforms will be discussed, and case studies will be shown that demonstrate sensitivity, quantification, ruggedness and multiplexing combined with aesthetics and user friendliness designed to drive adoption and minimize errors in the field.
Add to Calendar ▼2016-09-26 00:00:002016-09-28 00:00:00Europe/LondonPoint-of-Care Diagnostics and Global Health World Congress 2016Point-of-Care Diagnostics and Global Health World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2016-09-27 13:30:002016-09-27 14:30:00Europe/LondonHigh Performance Field-based Immunosensor Platforms Based on Next-Generation Lateral Flow TechnologyPoint-of-Care Diagnostics and Global Health World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
